

Oasmia wins sole rights to record patents in its own name and is awarded full legal costs

Uppsala, Sweden, March 24, 2021 – Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company, today announces that an arbitral tribunal in Stockholm, Sweden, has upheld Oasmia's right to record the assignment of its patents and patent applications in its own name.

In 2020, Oasmia was obliged to initiate arbitration to ensure the registration of its patents in accordance with transfer agreements previously made between Oasmia and Ardenia Investments Limited.

The arbitral tribunal also awarded all of Oasmia's costs related to the legal dispute to be borne by Ardenia Investments.

For More Information:

Oasmia Pharmaceutical AB

Francois Martelet, Chief Executive Officer

Phone: +46 18-50 54 40

E-mail: IR@oasmia.com

Consilium Strategic Communications (For Oasmia)

Jonathan Birt, Chris Welsh, Ashley Tapp

Phone: +44 (0)20 3709 5700

E-mail: oasmia@consilium-comms.com

About Oasmia Pharmaceutical AB

Oasmia is a specialty pharma company dedicated to improving the lives of patients by enhancing the intravenous delivery of established and novel drugs in significant diseases, including cancer. Product development is based on Oasmia's proprietary drug delivery platform™ which can be applied to medicines used in many therapeutic areas, to develop water soluble formulations of drugs that currently require chemical solubilizers for dissolution. The first product approved using this technology is Apealea® (paclitaxel micellar). Apealea has received market authorization in the European Union and several other territories for the treatment of first relapse in platinum-sensitive ovarian cancer, in combination with carboplatin. The Company is making Apealea accessible to patients through its partnership with Elevar Therapeutics, together with its existing commercial operations in the Nordic region. Oasmia's shares are traded on the Nasdaq Stockholm stock exchange (ticker: OASM). To find out more about Oasmia please visit www.oasmia.com.

This information is information that Oasmia Pharmaceutical is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-03-24 18:08 CET.

Attachments

[Oasmia wins sole rights to record patents in its own name and is awarded full legal costs](#)